ESMO 2026 - evERA: Which Biomarkers Matter? With Dr. Sara Tolaney

Dr. Sara Tolaney explores the evERA biomarker analysis, examining ctDNA, ESR1 mutations and what they could tell us about giredestrant plus everolimus after CDK4/6 inhibitor progression in HR-positive metastatic breast cancer.